Li Jing, Cao Xiaobin, Zhang Lulu, Liu Aichen, Liu Siyu, Chen Fengqi, Li Yutong, Ma Hanke, Sun Wenke, Ouyang Songyun, Dai Liping, Liu Jingjing
Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China.
BGI College, Zhengzhou University, Zhengzhou, China.
Cancer Epidemiol Biomarkers Prev. 2025 Mar 3;34(3):439-447. doi: 10.1158/1055-9965.EPI-24-1096.
Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non-small cell lung cancer (NSCLC).
A total of 1,155 plasma samples were divided into the verification and validation groups. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using ELISA. Western blotting and immunofluorescence analyses were performed to confirm the ELISA results.
Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation groups. The ELISA results were confirmed by Western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an AUC (95% confidence interval) of 0.806 (0.772-0.839) and 0.627 (0.584-0.670), respectively.
Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection.
These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.
自身抗体可在活检前轻易识别，且可能作为癌症检测的重要生物标志物。铁氧化还原蛋白1（FDX1）是铜死亡过程中的关键调节因子，影响肺癌预后。在本研究中，我们调查了抗FDX1自身抗体是否可作为检测非小细胞肺癌（NSCLC）的新型生物标志物。
共1155份血浆样本被分为验证组和确认组。采用酶联免疫吸附测定法（ELISA）检测414例NSCLC患者、327例良性肺结节（BPN）患者和414例正常对照（NC）中抗FDX1自身抗体的表达水平。进行蛋白质免疫印迹法和免疫荧光分析以确认ELISA结果。
在验证组和确认组中，NSCLC患者血浆抗FDX1自身抗体水平显著高于BPN患者和NC。蛋白质免疫印迹法和免疫荧光法证实了ELISA结果。抗FDX1自身抗体区分NSCLC与NC和BPN的曲线下面积（95%置信区间）分别为0.806（0.772 - 0.839）和0.627（0.584 - 0.670）。
我们的研究证明了抗FDX1自身抗体作为NSCLC检测新型生物标志物的潜在益处。
这些发现表明抗FDX1自身抗体可能有助于NSCLC的检测。
